Omega-3 supplier BASF will continue to produce the API for Amarin, as well as its competitor GlaxoSmithKline, despite an FDA panel saying that Amarin’s drug should not be approved for a broader population.
Last week, BASF officially opened a pharmaceutical grade omega-3 active pharmaceutical ingredient (API) facility on the Isle of Lewis, Scotland that it gained with the acquisition of Equateq earlier this year.
A facility operated by fatty acid specialist Equateq on the island of Lewis in Scotland has met with UK good manufacturing practice (GMP) standards for the production of lipid-based APIs for the drug industry.
Danish firm Pronova BioPharma announced this morning that it is to
double manufacturing capacity for its marine-derived active
pharmaceutical ingredient (API), following increased demand for its
omega-3 based drug.
New anti-breast cancer drugs could be developed after latest
research suggested that Omega-3, a fatty acid found in oily fish,
could be combined with an anaesthetic to reduce the ability of
breast cancer cells to develop into malignant...
Norway's Norsk Hydro has agreed to sell 80.1 per cent of its shares
in omega-3 producer Pronova Biocare to Norwegian industrial company
Ferd for NOK 165 million (€19.4m).
